KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Basic): 2017-2025

Historic EPS (Basic) for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$0.14.

  • Aquestive Therapeutics' EPS (Basic) fell 7.69% to -$0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 54.35%. This contributed to the annual value of -$0.51 for FY2024, which is 292.31% down from last year.
  • Per Aquestive Therapeutics' latest filing, its EPS (Basic) stood at -$0.14 for Q3 2025, which was down 0.00% from -$0.14 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' EPS (Basic) peaked at $0.15 during Q1 2023, and registered a low of -$0.73 during Q4 2021.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.13 (2024), whereas its average is -$0.10.
  • Per our database at Business Quant, Aquestive Therapeutics' EPS (Basic) tumbled by 371.43% in 2021 and then soared by 146.88% in 2023.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' EPS (Basic) stood at -$0.73 in 2021, then skyrocketed by 69.86% to -$0.22 in 2022, then surged by 40.91% to -$0.13 in 2023, then tumbled by 46.15% to -$0.19 in 2024, then fell by 7.69% to -$0.14 in 2025.
  • Its last three reported values are -$0.14 in Q3 2025, -$0.14 for Q2 2025, and -$0.24 during Q1 2025.